PharmaMar: Sylentis Presents New Data On A New Eye Drop siRNA For The Treatment Of Retinal Diseases Avoiding Intraocular Injections
MADRID, September 25, 2017 /PRNewswire/ --
• This new investigational treatment, based on RNA interference, reaches the retina when administered in eye drops. This feature is expected to positively affect patients' quality of life by eluding the use of current standard treatments administered by intraocular injections.
Sylentis presents, for the first time, positive data on the efficacy of SYL136001v10, a siRNA (small interference RNA) for the treatment of neovascular diseases of the retina such as Age-Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR). SYL136001v10 reaches the retina when administered topically, demonstrating that the siRNA may be applied in eye drops changing the treatment paradigm for patients suffering these diseases. "Currently, patients are treated in a hospital setting where they receive anti-VEGFs by intraocular injection. This procedure is not only painful and uncomfortable for the patient but also entails increasing financial commitments for our national health system," notes Covadonga Pañeda, R&D Manager at Sylentis, and principal author of the studies.
(Logo: http://photos.prnewswire.com/prnh/20150203/727958-b )
The data will be presented at the XIII Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) taking place in Bourdeaux, France between the 24th and the 27th of September and where the latest advances in oligonucleotide therapeutics will be presented.
Sylentis has identified NRARP (NOTCH-regulated Ankyrin Repeat Protein) as a potential target for the treatment of angiogenic diseases of the retina. NRARP is a key regulator of the molecular pathways leading to vessel formation; as such, the consequences of modulating the expression of this gene with RNAi has been studied in animal models of retinal neovascularization.
The results of the efficacy studies have shown that reduction of NRARP in the retina using RNAi leads to regression of neovascular lesions and that the lesion reductions observed are equivalent to those observed in response to anti-VEGF treatment, current standard treatment administered by intraocular injection.
Sylentis studies at the XIII Annual Meeting of the Oligonucleotide Therapeutics Society:
• Targeting NRARP with siRNA based compounds for the treatment of retinal neovascularization Session: September 24th 18:30 to 20:30 horas. Presenting author: Covadonga Pañeda et al. R&D Manager, Sylentis, España.
• Clinical and preclinical study correlation for SYL1001, a new treatment for dry eye disease (Posterboard number: Session: September 25th 17:00 to 19:30 horas. Presenting author: Covadonga Pañeda et al. R&D Manager, Sylentis, España.
Media Contacts:
Media Relations (+34-638-79-62-15)
Investor Relations (+34-914444500)
• This new investigational treatment, based on RNA interference, reaches the retina when administered in eye drops. This feature is expected to positively affect patients' quality of life by eluding the use of current standard treatments administered by intraocular injections.
Sylentis presents, for the first time, positive data on the efficacy of SYL136001v10, a siRNA (small interference RNA) for the treatment of neovascular diseases of the retina such as Age-Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR). SYL136001v10 reaches the retina when administered topically, demonstrating that the siRNA may be applied in eye drops changing the treatment paradigm for patients suffering these diseases. "Currently, patients are treated in a hospital setting where they receive anti-VEGFs by intraocular injection. This procedure is not only painful and uncomfortable for the patient but also entails increasing financial commitments for our national health system," notes Covadonga Pañeda, R&D Manager at Sylentis, and principal author of the studies.
(Logo: http://photos.prnewswire.com/prnh/20150203/727958-b )
The data will be presented at the XIII Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) taking place in Bourdeaux, France between the 24th and the 27th of September and where the latest advances in oligonucleotide therapeutics will be presented.
Sylentis has identified NRARP (NOTCH-regulated Ankyrin Repeat Protein) as a potential target for the treatment of angiogenic diseases of the retina. NRARP is a key regulator of the molecular pathways leading to vessel formation; as such, the consequences of modulating the expression of this gene with RNAi has been studied in animal models of retinal neovascularization.
The results of the efficacy studies have shown that reduction of NRARP in the retina using RNAi leads to regression of neovascular lesions and that the lesion reductions observed are equivalent to those observed in response to anti-VEGF treatment, current standard treatment administered by intraocular injection.
Sylentis studies at the XIII Annual Meeting of the Oligonucleotide Therapeutics Society:
• Targeting NRARP with siRNA based compounds for the treatment of retinal neovascularization Session: September 24th 18:30 to 20:30 horas. Presenting author: Covadonga Pañeda et al. R&D Manager, Sylentis, España.
• Clinical and preclinical study correlation for SYL1001, a new treatment for dry eye disease (Posterboard number: Session: September 25th 17:00 to 19:30 horas. Presenting author: Covadonga Pañeda et al. R&D Manager, Sylentis, España.
Media Contacts:
Media Relations (+34-638-79-62-15)
Investor Relations (+34-914444500)